Ketamine for Opioid Use Disorder

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorUniversity of Maryland, Baltimore

About this trial

The goal of this clinical trial is to learn if ketamine works to reduce craving for opioids in adults enrolled in methadone treatment for opioid use disorder. The main questions it aims to answer are:

* Does ketamine reduce craving for opioids in patients with opioid use disorder? * Does ketamine reduce symptoms of opioid withdrawal such as depression, pain, and poor sleep quality? * Do patients who take the low dose ketamine stay in methadone treatment longer, and/or have better treatment outcomes than those given the very low dose?

Researchers will compare two low doses of ketamine to see if ketamine works to reduce craving for opioids in adults enrolled in methadone treatment for opioid use disorder.

Participants will:

* Be given a low dose or a very low dose of ketamine 4 times over a period of 2 weeks * Visit with the study team one week prior to the first ketamine session, one week following the last ketamine session, at 30 days following the final ketamine session, and 90 days following the final ketamine session for checkups and tests

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 65 years old

Fulfillment of DSM-5/ICD-10 criteria for moderate-to-severe opioid use disorder

Acceptance into methadone treatment for opioid use disorder at the time of screening.

Adherence to lifestyle requirements for participation.

Disqualifiers

Pregnant and/or breastfeeding.

**Stage 2 Hypertension, defined by a systolic blood pressure (SBP) > 140 mmHg or a diastolic blood pressure (DBP) > 90 mmHg.

Abnormal oxygen saturation or abnormal heart rate (i.e. O2 saturation <95%, or HR <60 or >100bpm

Clinically significant abnormal findings for which study participation is deemed unsafe.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Treatment with Ketamine

    Drug

    Participants will receive four doses of ketamine spaced 1-6 days apart of 0.75 mg/kg intramuscular ketamine (n=25) for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.

  • Treatment with Very Low Dose Ketamine

    Drug

    Participants will receive four doses of very low dose ketamine (0.1mg.kg) (n=25) spaced 1-6 days apart for two weeks (first ketamine session must occur no later than 28 days post-intake). Individuals will be monitored for two hours post-dose by a clinician.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Treatment with KetamineExperimental treatment 1 intervention
Group B: Treatment with Very Low Dose KetamineActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Tonic craving (FORCAST) total scores

Faceted Opioid Research Craving Assessment for Substance use Treatment (FORCAST): A 26-item assessment of tonic craving that the person reports having felt over the prior one or two weeks. Participants indicate how much they disagree or agree with each statement on a scale that ranges from 0-6, with 0 representing "strongly disagree", 3 representing "neither agree nor disagree", and 6 representing "strongly agree". Higher scores indicate higher levels of craving. The minimum score is 0, and the maximum scores for each of the subscales are as follows: Preoccupation: 24 Negative Reinforcement: 30 Positive Reinforcement: 24 Motivation: 30 Lack of control: 24 Uneasiness: 24 Maximum total score for all subscales = 156

Time frame
Collected at 7 days pre- and post-ketamine, 30-, and 90-days post-final ketamine session

Secondary outcomes

1

Severity of depression symptoms

Montgomery-Asberg Depression Rating Scale (MADRS): a 10-item questionnaire of depression severity. The total score ranges from 0-60, with scores of 0-6 considered normal (non-depressed), 7-19 indicative of mild depression, 20-34 indicative of moderate depression, and 35-60 indicative of severe depression. Item 10 on the instrument will be used to monitor any changes in suicidal ideation throughout the trial.

Time frame
Completed at 7 days pre- and post-ketamine, 30-, and 90-days post final ketamine session
2

Cue-induced craving scores

Cue Reactivity Paradigm: our drug cue reactivity paradigm will be designed to elicit an acute craving state. We will present a series of opioid cue images continuously (total time \<5 min) via computer or tablet. Cues will be personalized based on each individual's drug use history as derived from baseline clinical assessments. For example, if a participant had no history of intravenous drug injection, we will not present opioid cue images containing injection paraphernalia like needles and instead will present images with opioid pills and/or powder. At the end of each one-minute session, participants will be asked to rate, on a scale of 1-10, "How much did you like the images you saw?", "How much do you want to use right now?", "How much do you want to avoid using right now?", "How much control do you feel you have over using right now" and "What is the maximum amount you would pay right now for a single dose of what you saw?"

Time frame
Collected at 7 days pre- and post-ketamine, 7 days pre- and post ketamine, ketamine administration days, 30-, and 90-days post-final ketamine session
3

Chronic pain ratings

Graded Chronic Pain Scale (GCPS): a six-item instrument that evaluates chronic pain severity (intensity and impact on life activities).

Time frame
Collected at 7 days pre- and post-ketamine, ketamine administration days, 30-, and 90-days post-final ketamine session
4

Number of methadone doses received at 90 days post final ketamine session

Study team will have access to clinic records to assess the number of methadone doses patients have received at 90 days post final ketamine session

Time frame
Collected through 90 days post final ketamine session

Other outcomes

1

Decision making test performance (risk and ambiguity tolerance)

Choice under risk and ambiguity (CRA) decision making task: On each trial, participants choose between a guaranteed $1 and a lottery. Each lottery has 2 possible outcomes: v or $0, where v ranges from $1.20 to $13.20. On half of the trials, v could be received with 1 of 3 known probabilities (p: 25%, 50%, or 75%); on the other half, the probability information is occluded and thus incompletely known (the ambiguity context). There are 3 levels of ambiguity: low (24% unknown), medium (50% unknown), and high (74% unknown). In reality, the true underlying probability in ambiguity trials is fixed at 50%. Different combinations of v, risk level, and ambiguity level are presented for 30 trials total. A modified utility model will be used which can extract the following parameters from participant decisions on these trials: * risk tolerance * ambiguity tolerance * choice stochasticity

Time frame
collected weekly through 90 days post final ketamine session via optional EMAs
2

Methadone dose (mg) at 90 days post final ketamine session

Study team will have access to clinic records of methadone dose (mg) received by participant at 90 days post final ketamine session

Time frame
collected through 90 days post final ketamine session
3

OUD treatment outcomes at 6-, 9-, and 12 months post study enrollment

Study team will have access to clinic records of methadone dose, number of methadone doses received, and frequency of negative drug screens though 12 months post study enrollment

Time frame
collected through 6-, 9-, and 12 months post study enrollment

Sponsors and contacts

Click on the lead sponsor to view all of their trials.